Charles Schwab has expanded its Schwab Crypto service, allowing most eligible U.S. clients to buy Bitcoin (BTC) and Ether (ETH) directly through their brokerage accounts. Each transaction carries a 0.75% fee, with Paxos handling custody and trade execution. The service excludes residents of New York and Louisiana but is now accessible to a broader client base beyond the initial rollout. This move integrates crypto trading into a major brokerage managing $13 trillion in assets and serving over 40 million U.S. users, potentially increasing crypto adoption among mainstream investors.
Charles Schwab's expansion of direct Bitcoin buying to U.S. clients is noted here with Pluang's market snapshot as of Oct 17, 2026 04:51 WIB: Among 50 major cryptocurrencies priced on Pluang, 10 rose and 39 fell today. Notable movers include BAT at Rp3.597 with a -8.25% change and 75% sell order activity, EOS at Rp12.649 up 8.13%, and CRV at Rp6.181 down 3.96% with 79% sell orders. The most notable figure is BAT's 75% sell order activity on Pluang.
Changan Automobile announced new partnerships covering seven European markets and launched its "with U" service program at Mondial de l’Auto 2026. This marks a shift from market entry to building a local ecosystem including manufacturing, sales, serv...
At the 2026 Mondial de l’Auto, Changan Automobile signed letters of intent with eight companies across seven European markets and launched its "with U" service program. This marks a strategic move to build a strong local ecosystem combining manufactu...
Northland Power Inc. announced it will release its third quarter 2026 financial results after market close on November 12, 2026. The company will host an earnings call and webcast on November 13 at 9:00 a.m. ET, providing investors an opportunity to ...
Several daily leveraged ETFs tied to tech and crypto-related stocks dropped sharply, with declines over 20%. Notable falls include GraniteShares 2x Long NBIS Daily ETF down 24.5% and Leverage Shares 2x Long CRWV Daily ETF down 23.9%. These ETFs aim t...
Recent biotech IPOs Iambic Therapeutics and City Therapeutics saw significant price jumps, rising 25.9% and 22.2% respectively after their market debuts, raising substantial capital. Inverse leveraged ETFs SMCZ and SMST also gained sharply as their u...
